Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dihydroergotoxine→

Dihydroergotoxine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
11032-41-0
Molecular formula
Not available
Molecular weight
679.8 g/mol
Drug class
Ergot alkaloid mixtureadrenergic, serotonergic and dopaminergic receptor modulator
Mechanism of action
Contains dihydroergocristine, dihydroergocornine and dihydroergocryptine isomers, which interact with adrenergic, serotonergic and dopaminergic receptors. A single proven clinical mechanism for historical cognitive or vascular uses is not established.
Indications / reported uses
  • Historical or regional use in ergot-alkaloid mixtures for cognitive symptoms or peripheral vascular complaints; these uses are not broadly supported as current approved indications and should not be confused with uterotonic ergot alkaloids

Sources: NLM MeSH — Dihydroergotoxine · PubMed — Dihydroergotoxine clinical evidence · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dihydroergotoxine Environmental Risk Assessment (ERA) (the Dihydroergotoxine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.